Department of Rheumatology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, 100020 Beijing, China.
Rheumatol Int. 2010 Jan;30(3):341-8. doi: 10.1007/s00296-009-0966-8. Epub 2009 May 23.
Pulmonary arterial hypertension (PAH) is a severe clinical and pathophysiologic syndrome with no effective treatment at present. Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), has been applied widely to the treatment of connective tissue diseases with the effect of immunosuppressant. Its anti-proliferation has been found recently. Thereby, we tried to examine the effects of MMF on rats with PAH which was induced by monocrotaline injection, so as to investigate the mechanisms of treatment on PAH by MMF. The results substantiated that MMF therapy can alleviate thickening of pulmonary arterial walls and inhibit abnormal vascular remodeling, and the MPA concentrations which demonstrated efficacy in this study are within clinical applicable range, suggesting huge potentiality of MMF in the treatment of human PAH.
肺动脉高压(PAH)是一种严重的临床和病理生理综合征,目前尚无有效治疗方法。霉酚酸酯(MMF)是霉酚酸(MPA)的前体药物,已广泛应用于结缔组织疾病的治疗,具有免疫抑制作用。最近发现其具有抗增殖作用。因此,我们试图研究霉酚酸酯(MMF)对野百合碱诱导的肺动脉高压大鼠的作用,以探讨 MMF 治疗 PAH 的机制。结果证实,MMF 治疗可减轻肺血管壁的增厚并抑制异常血管重塑,本研究中显示疗效的 MPA 浓度在临床适用范围内,提示 MMF 在治疗人类 PAH 方面具有巨大潜力。